Finotti, Alessia
Fabbri, Enrica
Lampronti, Ilaria
Gasparello, Jessica
Borgatti, Monica
Gambari, Roberto
Article History
First Online: 4 January 2019
Compliance with Ethical Standards
:
: All the authors (AF, EF, IL, JG, MB and RG) declare they have no conflicts of interest that are directly relevant to the content of this review.
: This study was partially supported by the following funds to RG: EU FP7 THALAMOSS Project (THALAssaemia MOdular Stratification System for personalized therapy of β-thalassemia; Grant number [306201]-FP7-Health-2012-INNOVATION-1), Fondazione CARIPARO and Associazione Veneta per la Lotta alla Talassemia (AVLT) Rovigo. In addition, this study was supported by Fondazione Fibrosi Cistica (FFC), Project “Revealing the microRNAs-Transcription factors network in cystic fibrosis: from microRNA therapeutics to precision medicine” (CF-miRNA-THER, FFC#7/2018). This study is also partially supported by Wellcome Trust and by Agenzia Italiana del Farmaco (AIFA). All funding bodies had no role in the design of the study, in the collection, analysis, and interpretation of data, or in writing the manuscript.